中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 40 Issue 12
Dec.  2024
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(12): 2424-2429

Effectiveness of fibrosis-4 versus aspartate aminotransferase-to-platelet ratio index in evaluating liver fibrosis degree in patients with chronic HBV infection

DOI: 10.12449/JCH241212

  • Department of Infectious Diseases，The First Affiliated Hospital of Guangxi Medical University，Nanning 530500，China

Research funding:

National Natural Science Foundation of China (8216030105)

More Information
  • Corresponding author: SU Minghua， smh9292@163.com （ORCID： 0000-0001-7831-6580）
  • Received Date: 2023-11-14
  • Accepted Date: 2024-01-25
  • Published Date: 2024-12-25
    Abstract
  •   Objective  To investigate the performance of fibrosis-4 （FIB-4） versus aspartate aminotransferase-to-platelet ratio index （APRI） in predicting advanced liver fibrosis and disease progression in patients with chronic HBV infection.  Methods  A total of 497 patients with chronic HBV infection who underwent liver biopsy in The First Affiliated Hospital of Guangxi Medical University from February 2013 to December 2022 were enrolled， among whom 404 were enrolled in a retrospective study and 75 were enrolled in a prospective study. Related indicators were collected， including demographic features （sex and age）， biochemical indices （alanine aminotransferase ［ALT］ and aspartate aminotransferase ［AST］）， and platelet count， and FIB-4 and APRI were calculated. The Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups， and the Kruskal-Wallis H test was used for comparison between multiple groups； the chi-square test was used for comparison of categorical data between groups. The area under the ROC curve （AUC） was used to assess the ability of APRI and FIB-4 in evaluating liver fibrosis degree and disease progression in patients with chronic HBV infection.  Results  In the retrospective analysis， compared with the FIB-4<2.67 group， the FIB-4≥2.67 group had a significantly higher proportion of the patients who were diagnosed with liver cirrhosis or hepatocellular carcinoma （66.19% vs 47.54%， χ²=12.75， P<0.001）. The medians of FIB-4 and APRI increased significantly with liver fibrosis degree from F0 to F4 （H=42.5 and 35.9， both P<0.001）. As for the fibrosis stage of F0-F4， the median of FIB-4 was significantly higher than that of APRI in the patients with the same fibrosis stage （H=59.71， P<0.001）. FIB-4 and APRI had a similar AUC for predicting stage F3 fibrosis （0.67 vs 0.65， Z=0.71， P=0.480）， while FIB-4 had a higher AUC for predicting stage F4 fibrosis than APRI （0.72 vs 0.64， Z=10.50， P<0.001）. In the prospective study cohort， FIB-4 and APRI showed an increasing trend over time in predicting disease progression （chronic hepatitis B to liver cirrhosis）， with an AUC of 0.718 （95% confidence interval ［CI］： 0.476‍ ‍—‍ ‍0.760） and 0.555 （95%CI： 0.408‍ ‍—‍ ‍0.703）， respectively， and FIB-4 had a significantly higher accuracy than APRI in predicting disease progression （χ2=12.44， P<0.001）.  Conclusion  FIB-4 and APRI can be used to evaluate advanced liver fibrosis （F3 and F4） and predict disease progression， and FIB-4 is superior to APRI in certain aspects.

     

    • FullText(HTML)
    • References(21)
  • [1]
    ROEHLEN N, CROUCHET E, BAUMERT TF. Liver fibrosis: Mechanistic concepts and therapeutic perspectives[J]. Cells, 2020, 9( 4): 875. DOI: 10.3390/cells9040875.
    [2]
    SETO WK, LO YR, PAWLOTSKY JM, et al. Chronic hepatitis B virus infection[J]. Lancet, 2018, 392( 10161): 2313- 2324. DOI: 10.1016/S0140-6736(18)31865-8.
    [3]
    KUMARI B, KUMAR R, SHARMA S, et al. Diagnostic accuracy of FIB-4 and FIB-5 scores as compared to fibroscan for assessment of liver fibrosis in patients with non-alcoholic fatty liver disease[J]. Cureus, 2021, 13( 8): e17622. DOI: 10.7759/cureus.17622.
    [4]
    DAY JW, ROSENBERG WM. The enhanced liver fibrosis(ELF) test in diagnosis and management of liver fibrosis[J]. Br J Hosp Med(Lond), 2018, 79( 12): 694- 699. DOI: 10.12968/hmed.2018.79.12.694.
    [5]
    SINGH S, MUIR AJ, DIETERICH DT, et al. American Gastroenterological Association Institute technical review on the role of elastography in chronic liver diseases[J]. Gastroenterology, 2017, 152( 6): 1544- 1577. DOI: 10.1053/j.gastro.2017.03.016.
    [6]
    ITAKURA J, KUROSAKI M, SETOYAMA H, et al. Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis[J]. J Gastroenterol, 2021, 56( 5): 470- 478. DOI: 10.1007/s00535-021-01782-3.
    [7]
    SHAH AG, LYDECKER A, MURRAY K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2009, 7( 10): 1104- 1112. DOI: 10.1016/j.cgh.2009.05.033.
    [8]
    RASMUSSEN DN, THIELE M, JOHANSEN S, et al. Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease[J]. J Hepatol, 2021, 75( 5): 1017- 1025. DOI: 10.1016/j.jhep.2021.05.037.
    [9]
    LU M, LI J, ZHANG T, et al. Serum biomarkers indicate long-term reduction in liver fibrosis in patients with sustained virological response to treatment for HCV infection[J]. Clin Gastroenterol Hepatol, 2016, 14( 7): 1044- 1055. DOI: 10.1016/j.cgh.2016.01.009.
    [10]
    SCHMID P, BREGENZER A, HUBER M, et al. Progression of liver fibrosis in HIV/HCV co-infection: a comparison between non-invasive assessment methods and liver biopsy[J]. PLoS One, 2015, 10( 9): e0138838. DOI: 10.1371/journal.pone.0138838.
    [11]
    GORDON SC, LAMERATO LE, RUPP LB, et al. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population[J]. Clin Gastroenterol Hepatol, 2014, 12( 5): 885- 893. DOI: 10.1016/j.cgh.2013.09.062.
    [12]
    LI J, GORDON SC, RUPP LB, et al. Long-term progression of viral load and serum markers of fibrosis among treated and untreated patients with chronic hepatitis B[J]. J Gastroenterol Hepatol, 2017, 32( 6): 1250- 1257. DOI: 10.1111/jgh.13667.
    [13]
    LI Q, REN X, LU C, et al. Evaluation of APRI and FIB-4 for noninvasive assessment of significant fibrosis and cirrhosis in HBeAg-negative CHB patients with ALT ≤2 ULN: A retrospective cohort study[J]. Medicine(Baltimore), 2017, 96( 12): e6336. DOI: 10.1097/MD.0000000000006336.
    [14]
    XIAO G, YANG J, YAN L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis[J]. Hepatology, 2015, 61( 1): 292- 302. DOI: 10.1002/hep.27382.
    [15]
    GRAF C, MONDORF A, KNOP V, et al. Evaluation of point shear wave elastography using acoustic radiation force impulse imaging for longitudinal fibrosis assessment in patients with HBeAg-negative hbv infection[J]. J Clin Med, 2019, 8( 12): 2101. DOI: 10.3390/jcm8122101.
    [16]
    SANAI FM, FARAH T, ALBELADI K, et al. Diminished accuracy of biomarkers of fibrosis in low replicative chronic hepatitis B[J]. BMC Gastroenterol, 2017, 17( 1): 101. DOI: 10.1186/s12876-017-0658-x.
    [17]
    AMERNIA B, MOOSAVY SH, BANOOKH F, et al. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran[J]. BMC Gastroenterol, 2021, 21( 1): 453. DOI: 10.1186/s12876-021-02038-3.
    [18]
    SHIHA G, SEIF S, ELDESOKY A, et al. A simple bedside blood test(Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-significant and significant fibrosis in patients with chronic hepatitis C[J]. Hepatol Int, 2017, 11( 3): 286- 291. DOI: 10.1007/s12072-017-9796-z.
    [19]
    GRAUPERA I, THIELE M, SERRA-BURRIEL M, et al. Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population[J]. Clin Gastroenterol Hepatol, 2022, 20( 11): 2567- 2576. DOI: 10.1016/j.cgh.2021.12.034.
    [20]
    HAYMART MR, MILLER DC, HAWLEY ST. Active surveillance for low-risk cancers-a viable solution to overtreatment?[J]. N Engl J Med, 2017, 377( 3): 203- 206. DOI: 10.1056/NEJMp1703787.
    [21]
    JOHANSSON M, JØRGENSEN KJ, BRODERSEN J. The benefits of screening-and its harms[J]. Lancet, 2016, 388( 10044): 563- 564. DOI: 10.1016/S0140-6736(16)31219-3.
    • Relative Articles

  • Relative Articles

    [1]Long HUANG, Hongqian LIANG, Aoli REN, Minghua SU, Bobin HU, Qingmei LI, Tumei SU, Qianbing YIN, Yanfei FENG, Jianning JIANG. Diagnostic value of serum extra-spindle pole-like protein 1 in the progression of hepatitis B virus-related liver fibrosis[J]. Journal of Clinical Hepatology, 2024, 40(9): 1785-1789. doi: 10.12449/JCH240911
    [2]Xueping ZHANG, Xiaofei SHANG, Xiuhui LI. Advances in integrated traditional Chinese and Western medicine diagnosis and treatment of hepatic fibrosis[J]. Journal of Clinical Hepatology, 2023, 39(2): 284-289. doi: 10.3969/j.issn.1001-5256.2023.02.006
    [3]Huanming XIAO, Meijie SHI, Yubao XIE, Xiaoling CHI. Advances and thoughts in traditional Chinese medicine diagnosis and treatment of chronic hepatitis B-related liver fibrosis[J]. Journal of Clinical Hepatology, 2023, 39(2): 260-266. doi: 10.3969/j.issn.1001-5256.2023.02.002
    [4]Baisheng HUANG, Lanxin OU, Yingjie ZHANG, Meijie SHI, Sheng LI, Huanming XIAO, Xiaoling CHI. Value of traditional noninvasive fibrosis models in diagnosis of significant liver fibrosis in patients with chronic hepatitis B and metabolic associated fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(9): 2110-2116. doi: 10.3969/j.issn.1001-5256.2023.09.012
    [5]Radiology of Infection Sub-branch, Radiology Branch, Chinese Medical Association, Committee on Radiology of Infection, Radiology Branch, Chinese Medical Doctor Association, Radiology Committee on Infectious and Inflammatory Disease, Chinese Research Hospital Association, Radiology of Infection Branch, Working and Treating Committee of HIV/AIDS and STD Association, Radiology of Infectious Disease Management Sub-branch, Infectious Disease Management Branch, Hospital Management Association in China, Beijing Imaging Diagnosis and Treatment Technology Innovation Alliance. Consensus on imaging techniques and diagnostic criteria for hepatitis B virus related early hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(4): 787-791. doi: 10.3969/j.issn.1001-5256.2021.04.013
    [6]Wang Yan, Li BingShun, Wang JianBin. Study about ultrasonic and fibrosis parameters with diagnose of hepatic fibrosis[J]. Journal of Clinical Hepatology, 2008, 24(1): 31-33.
    [7]Jiang ZhongSheng, Wen XiaoFeng, Ke Liu, Tan Chuan, Chen Nian, Li MinJi. The diagnostic value of APRI and Forns index for liver fibrosis of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2008, 24(6): 423-425.
    [8]Ou XiaoJuan, Wang XiaoMing, Wang BaoEn, Wang TaiLing, Ma Hong, You Hong, Jia JiDong. Reevaluation of diagnostic value of serum fibrosis markers to liver fibrosis staging in patients with chronic hepatits B[J]. Journal of Clinical Hepatology, 2007, 23(6): 413-414.
    [9]Xia Qi, Fu JieHai, Cai WeiMin, Liu RongHua. Diagnostic value of AST/PLT and GGT/PLT for hepatic fibrosis.[J]. Journal of Clinical Hepatology, 2007, 23(5): 364-366.
    [10]Ge WenSong, Yao DingKang, Zhu Liang. Preliminary study on proteomic patterns in hepatic tissue to identify HBV related hepatic firbrosis.[J]. Journal of Clinical Hepatology, 2007, 23(5): 357-359.
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (302) PDF downloads(39) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2329]YesterdayPV[4431]TodayIP[2142]TodayPV[4743]Online[37]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return